Signature line: Noah Fromson

On March 8, the U.S. Food and Drug Administration issued a new regulatory approval for the use of semaglutide (brand Wegovy) to “reduce the risk of cardiovascular death, heart attack, and stroke in adults with cardiovascular disease who are obese or overweight.” Approved for adaptation. The FDA notes that it should be used in addition to a reduced-calorie diet and increased physical activity. As we address this, the University of Michigan has experts in both cardiovascular disease prevention and weight management/obesity medicine who are available for interviews regarding this development. Michigan Health Frankel Cardiovascular Center. Brandt is a cardiologist/lipidologist and clinical instructor in internal medicine and cardiology at the UM School of Medicine.

• Dr. Andrew Craftson is director of the Weight Navigation Program and Postbariatric Endocrinology Clinic at the University of Michigan. Craftson is an endocrinologist/obesity medicine specialist and clinical associate professor of internal medicine and endocrinology at the UM School of Medicine. If you are interested, we would be happy to interview you. Noah Fromson (he/him/him) Senior Public Relations Specialist and Medical Content Producer Frankel Cardiovascular Center, Neuroscience, Kern Pavilion, Broadcast Clip C: (216) 509-8604